NCT03973931Completed
Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications
Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications (The Nudge Study)
Source: ClinicalTrials.gov · Last updated 2 Apr 2025
Brief summary (registry, in English)
The study plans to learn if sending different text messages, serving as reminders or encouragement, may help patients take their medication more often if they have had trouble keeping up with their medicines.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 9501 (actual)
- First submitted
- 31 May 2019
- Start date
- 1 Jul 2019
- Primary completion date
- 25 May 2023
- Lead sponsor
- University of Colorado, Denver
- NCT number
- NCT03973931
What you commit to
- Study type: Interventional
- Participants enrolled: 9501
- From 1 Jul 2019 to the primary completion date, 25 May 2023
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who do not have a mailing address listed in EHR;
- Patients who do not have a landline or cellphone listed in EHR;
- Currently pregnant if denoted in the EHR at the time of the data pull;
- Patients with a mailing address outside of the state of Colorado;
- Patients that do not speak either English or Spanish.
Who the study is looking for
- Patients with the following cardiovascular conditions and respective medication classes:
- Hypertension (Beta-blockers \[B-blockers)\], Calcium Channel Blocker \[CCB\], Angiotensin converting enzyme inhibitors (ACEi), Angiotensin Receptor Blockers \[ARB\], or Thiazide diuretic)
- Hyperlipidemia (HMG CoA reductase inhibitor \[Statins\])
- Diabetes (Alpha-glucosidase inhibitors, Biguanides, DPP-4 inhibitors, Sodium glucose transport inhibitor, Meglitinides, Sulfonylureas, Thiazolidinediones, or statins Coronary artery disease P2Y12 inhibitor \[Clopidogrel, Ticagrelor, Prasugrel, Ticlopidine\], B-blockers, ACEi or ARB or statins)
- Atrial fibrillation (Direct oral anticoagulants, B-blockers, CCB)
Age in the registry: 18 years to 89 years · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCHealth Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
| University of Colorado Denver Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
| VA Eastern Colorado Health Care System Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
| Denver Health and Hospital Authority Coordinator of this site? Confirm its status | Denver | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.